Antigens Patents (Class 435/69.3)
  • Patent number: 11998635
    Abstract: Disclosed are extracellular vesicles comprising an engineered targeting protein for targeting the extracellular vesicles to target cells. The targeting protein is a fusion protein that includes a ligand, an engineered glycosylation site, and an exosome-targeting domain. Exemplary extracellular vesicles may include but are not limited to exosomes.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: June 4, 2024
    Assignee: Northwestern University
    Inventors: Joshua N. Leonard, Michelle E. Hung
  • Patent number: 11988669
    Abstract: The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and/or autoimmune diseases.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: May 21, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Julia Leibold
  • Patent number: 11981707
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: September 11, 2023
    Date of Patent: May 14, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Patent number: 11866768
    Abstract: This disclosure provides methods, systems, compositions, and kits for the multiplexed detection of a plurality of analytes in a sample. In some examples, this disclosure provides methods, systems, compositions, and kits wherein multiple analytes may be detected in a single sample volume by acquiring a cumulative measurement or measurements of at least one quantifiable component of a signal. In some cases, additional components of a signal, or additional signals (or components thereof) are also quantified. Each signal or component of a signal may be used to construct a coding scheme which can then be used to determine the presence or absence of any analyte.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: January 9, 2024
    Assignee: California Institute of Technology
    Inventors: Emil P. Kartalov, Aditya Rajagopal, Axel Scherer
  • Patent number: 11779606
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: October 10, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 11767345
    Abstract: The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: September 26, 2023
    Assignees: TOAGOSEI CO., LTD, National University Corporation Hokkaido University
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Patent number: 11730799
    Abstract: A method of vaccinating a subject is provided, where a cancer protective response is produced. A first vaccine comprises an adenovirus vector comprising at least one nucleic acid molecule that produces a cancer protective response is administered, followed by one or more second vaccines comprising an alphavirus replicon particle comprising RNA comprising or produced from the nucleic acid molecule. In an embodiment the cancer is prostate cancer.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: August 22, 2023
    Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES GOVERNMENT DEPARTMENT OF VETERANS AFFAIRS
    Inventors: David M. Lubaroff, Delbert L. Harris
  • Patent number: 11693009
    Abstract: Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: July 4, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Christopher Chang
  • Patent number: 11684669
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: June 27, 2023
    Assignees: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
  • Patent number: 11667695
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: June 6, 2023
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Turner
  • Patent number: 11649264
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: May 16, 2023
    Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite De Claude Bernard Lyon 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • Patent number: 11572391
    Abstract: Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: February 7, 2023
    Assignee: Oral Health Australia PTY Ltd
    Inventors: Eric Charles Reynolds, Neil Martin O'Brien Simpson, Keith J. Cross, Nada Slakeski
  • Patent number: 11528289
    Abstract: Security mechanisms for content delivery networks (“CDNs”) are disclosed herein. One security mechanism can be used to mitigate or prevent dynamic content attacks. A system can execute a CDN manager to perform operations. In particular, the CDN manager can receive a plurality of hypertext transfer protocol (“HTTP”) requests, and parse a plurality of headers from the plurality of HTTP requests to determine a plurality uniform resource locators (“URLs”). The CDN manager can generate a plurality of web page images associated with the plurality of URLs. The CDN manager can execute a machine learning algorithm, such as a convolution neural network, to perform an analysis of the plurality of web page images. Based upon the analysis of the plurality of web page images, the CDN manager can determine whether the plurality of HTTP requests are for the same web page, which can be indicative of a dynamic content attack.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: December 13, 2022
    Assignee: AT&T Intellectual Property I, L.P.
    Inventors: Joseph Soryal, Dylan C. Reid
  • Patent number: 11472882
    Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: October 18, 2022
    Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.
    Inventors: Rudi Bao, Haiqing Hua, Suxia Liu, Fujun Zhang, Ting Wang
  • Patent number: 11464846
    Abstract: The invention relates to a mutated HPV66 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV66 and HPV56, or HPV66, HPV56 and HPV53), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: October 11, 2022
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH, CO., LTD.
    Inventors: Shaowei Li, Xinlin Liu, Yurou Yang, Jie Chen, Daning Wang, Ningshao Xia
  • Patent number: 11414461
    Abstract: The disclosure relates to compositions, assays, methods and kits comprising one or more amino acid sequences of a filovirus protein, or a fragment thereof, which find use in the detection of a filovirus infection and/or the presence of antibodies specific for a filovirus in a biological sample.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: August 16, 2022
    Assignee: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventors: Robert G. Ulrich, Teddy Kamata
  • Patent number: 11235045
    Abstract: The present disclosure relates to rodent hepadnavirus core antigens including one or more B cell and T cell epitopes of a malaria parasite antigen. More specifically, the present disclosure relates to hybrid woodchuck hepadnavirus core antigens that have been modified to diminish the antibody response to the core antigen so as to enhance the antibody response to fragments of malaria antigen(s) included therein.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: February 1, 2022
    Assignee: VLP Biotech, Inc.
    Inventors: David R. Milich, David C. Whitacre
  • Patent number: 11231720
    Abstract: A moving robot comprises a floor sensing unit comprised of a plurality of transmitters, for which different sensing distances are set, and a single receiver, and, since a floor state is sensed using a plurality of sensors, it is possible to sense a normal floor states, an obstacle or a cliff present on a floor, and a long-distance state at a distance farther than the normal floor state, thereby preventing wrong sensing of a cliff due to an obstacle, and, since whether to keep traveling is set depending on the obstacle and a traveling speed is controlled, even an area previously not allowed to enter due to the wrong sensing may be cleaned and therefore a cleaning area may be increased.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 25, 2022
    Assignee: LG ELECTRONICS INC.
    Inventors: Sihyuk Yi, Jaehwan Ko, Hyukdo Kweon
  • Patent number: 11230590
    Abstract: In one aspect, the present invention is directed to a method for preventing or treating necrotic enteritis by administering a hyperimmunized egg product obtained from an egg-producing animal to an avian. The hyperimmunized egg product may contain an antibody specific to an antigen selected from the group consisting of Clostridium perfringens ?-toxin, Clostridium perfringens elongation factor Tu (EF-Tu), Clostridium perfringens necrotic enteritis B-like (NetB) toxin, Clostridium perfringens Pyruvate: Ferredoxin oxidoreductase (PFO), and Eimeria tenella elongation factor 1-alpha.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 25, 2022
    Assignees: Arkion Life Sciences, LLC, United States of America, as Represented by the Secretary of Agriculture
    Inventors: Hyun S. Lillehoj, Earnest W. Porta, Samuel V. Walker, Leslie A. Confer, Ujvala Deepthi Gadde, Cyril Gay
  • Patent number: 11220680
    Abstract: The present disclosure provides a polypeptide including an anti-fibrin antibody and a serine protease moiety of human tissue plasminogen activator. Methods for treating thrombosis in a subject in need of such treatment using such polypeptide are also disclosed.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: January 11, 2022
    Assignee: IMMUNWORK INC.
    Inventors: Tse-Wen Chang, Hsing-Mao Chu, Wei-Ting Tian, Ting-Wei Chang, Ming-Yu Hsieh
  • Patent number: 11124555
    Abstract: A fusion polypeptide, comprising an inclusion body tag fused to at least one polypeptide of interest, is provided. The inclusion body tag comprises an inclusion body forming (IBF) amino acid sequence selected from X14X15AX17X18X19GLTVA GMLG and sequences having at least 71% identity thereto. Also provided are inclusion bodies comprising the fusion polypeptide, as well as nucleic acids, expression vectors, host cells and methods for its production.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: September 21, 2021
    Assignee: ABERA BIOSCIENCE AB
    Inventors: Wouter Simon Petrus Jong, Joen Luirink
  • Patent number: 10983121
    Abstract: Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: April 20, 2021
    Assignees: QIAGEN Sciences LLC, Biopeptides Corp., Gundersen Lutheran Medical Foundation, Inc.
    Inventors: Steven M. Callister, Jeff Boyle, Misato Miyamasu, Raymond Dattwyler, Paul M. Arnaboldi
  • Patent number: 10626161
    Abstract: The present invention provides methods and compositions for optimally co-expressing in a primate subject a tyrosylprotein sulfotransferase (TPST) and a lentiviral gp120-binding molecule to provide potent and long term protection against lentiviral infections.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 21, 2020
    Assignee: The Scripps Research Institute
    Inventors: Matthew Gardner, Michael Farzan
  • Patent number: 10196089
    Abstract: A method of controlling a backing system for a vehicle and trailer assembly comprises initiating a backing system mode with an electronic control unit (ECU) for the backing system when a start system input is received from a control device. At least one input is received by the ECU from the control device which includes information about a desired vehicle action. The ECU interprets from the at least one input the desired vehicle action and calculates a required vehicle response to achieve the desired vehicle action. The ECU then sends a request to at least one vehicle system to perform the calculated vehicle response.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 5, 2019
    Assignee: Continental Automotive Systems, Inc.
    Inventors: Brandon Herzog, Andre Payant, Jeremy J. McClain, Ibro Muharemovic, Graham Fletcher, Jeffrey Weber, Dominik Froehlich, Steffen Linkenbach, David Agnew
  • Patent number: 10125373
    Abstract: A single vector or multiple separate vectors that contain two or more non-competing replicons for transient expression of the heavy and light chains of Rituximab in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures to optimize the expression is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of the multi-replicon single vector system for producing Rituximab in plant cells.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: November 13, 2018
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Hugh Mason, Charles Arntzen, Sun Hee Rosenthal, Sean Winkle, Andrew Diamos
  • Patent number: 10047149
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: August 14, 2018
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carla Emolo, Andrea DeDent
  • Patent number: 9968668
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 15, 2018
    Assignee: The University of Chicago
    Inventors: Molly McAdow, Andrea Dedent, Alice Cheng, Carla Emolo, Dominique Missiakas, Olaf Schneewind
  • Patent number: 9963698
    Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 8, 2018
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Michael Wayne Graham, Robert Norman Rice, Peter Michael Waterhouse
  • Patent number: 9833511
    Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: December 5, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
  • Patent number: 9821048
    Abstract: The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ.ID.No. 1, whereby such region is defined by (a) amino acid positions 150 to 200 of the amino acid sequence according to SEQ.ID.No.1, or (b) amino acid positions 410 to 480 of the amino acid sequence according to SEQ.ID.No.1, and whereby the polypeptide is suitable to elicit an immune response which is capable of inhibiting the catalytic activity of HPGGT.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 21, 2017
    Assignee: IMEVAX GMBH
    Inventors: Markus Gerhard, Christian Schmees, Christian Prinz
  • Patent number: 9770517
    Abstract: Described herein are compositions and methods of use of antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody or antigen-binding fragment thereof, conjugated to one or more cytotoxic drugs. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. More preferably, the antibody is humanized. Preferably the drug is SN-38, pro-2-pyrrolinodoxorubicin, paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD or MMAF. The compositions and methods are of use to treat Trop-2 expressing cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer. Preferably, the cancer is one that is resistant to one or more standard cancer therapies. More preferably, the anti-Trop-2 antibody binds to Trop-2 expressed on normal cells, but administration of the anti-Trop-2 ADC to human cancer patients at a therapeutically effective dosage produces only limited toxicity.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: September 26, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Patent number: 9701738
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria, in certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 11, 2017
    Assignee: The University of Chicago
    Inventors: Molly McAdow, Carla Emolo, Dominique Missiakas, Olaf Schneewind
  • Patent number: 9556281
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: January 31, 2017
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carla Emolo, Andrea DeDent
  • Patent number: 9494608
    Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: November 15, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
  • Patent number: 9463227
    Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 11, 2016
    Assignees: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: John Rothman, Anu Wallecha, Reshma Singh, Donald A. Harn, Jr., Yvonne Paterson
  • Patent number: 9402890
    Abstract: The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: August 2, 2016
    Assignee: UAB Research Foundation
    Inventors: Ilya Frolov, Elena Frolova
  • Patent number: 9295720
    Abstract: The invention relates to treatment of prostate cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of a prostatic tumor cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment of prostate cancer. Said immunogenic polypeptides are provided by the zona pellucida (ZP) (glyco)proteins. ZP (glyco)proteins and fragments thereof that can induce a CD8+ and/or CD4+ T cell response as well as nucleic acid sequences encoding them can suitably be used in the present immunotherapeutic strategies.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: March 29, 2016
    Assignee: PANTARHEI BIOSCIENCE B.V.
    Inventor: Herman Jan Tijmen Coelingh Bennink
  • Patent number: 9144607
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 29, 2015
    Assignee: Novavax, Inc.
    Inventors: Robin A. Robinson, Peter M. Pushko
  • Patent number: 9125864
    Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: September 8, 2015
    Assignee: Novartis AG
    Inventors: Renata Maria Grifantini, Erika Bartolini, Oretta Finco, Guido Grandi
  • Patent number: 9090676
    Abstract: The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ. ID. No. 1, whereby such region is defined by (a) amino acid positions 150 to 200 of the amino acid sequence according to SEQ. ID. No. 1, or (b) amino acid positions 410 to 480 of the amino acid sequence according to SEQ. ID. No. 1, and whereby the polypeptide is suitable to elicit an immune response which is capable of inhibiting the catalytic activity of HPGGT.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: July 28, 2015
    Assignee: IMEVAX GMBH
    Inventors: Markus Gerhard, Christian Schmees, Christian Prinz
  • Patent number: 9079048
    Abstract: A cosmetic or dermopharmaceutical composition comprising enkephalin-derived peptides of general formula (I) for reducing and/or eliminating facial wrinkles is disclosed. The cosmetic or dermopharmaceutical composition can be applied to the skin, preferably skin of the face, to reduce and/or eliminate facial wrinkles, such facial expression wrinkles. Use of the peptide of general formula (I) in the preparation of a cosmetic or dermopharmaceutical composition for reducing and/or eliminating facial wrinkles is also disclosed.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: July 14, 2015
    Assignee: Lipotec, S.A.
    Inventors: Antonio Vincente Ferrer Montiel, Juan Cebrián Puche, Arturo Puig Montiel
  • Publication number: 20150147347
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • Publication number: 20150141616
    Abstract: Intermolecular disulfide stabilized foldon polypeptides are provided.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Yuan Lu, James R. Swartz
  • Publication number: 20150140027
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 21, 2015
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Publication number: 20150140024
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: December 17, 2010
    Publication date: May 21, 2015
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 9034598
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: May 19, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Publication number: 20150132331
    Abstract: Vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified HA stem domain in a trimeric configuration.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 14, 2015
    Inventors: Yuan Lu, James R. Swartz
  • Publication number: 20150132334
    Abstract: Provided herein are methods and compositions for displaying a polypeptide on a tubular structure and uses of such displayed polypeptides in the production of antibodies or vaccines.
    Type: Application
    Filed: February 22, 2013
    Publication date: May 14, 2015
    Inventors: John Mekalanos, Marek Basler
  • Patent number: 9028844
    Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: May 12, 2015
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
  • Publication number: 20150125421
    Abstract: The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 7, 2015
    Inventor: Mark D. Mannie